Clinical bottom line
In pediatric patients presenting with acute severe asthma exacerbations requiring emergency intervention, prompt administration of systemic corticosteroids combined with inhaled bronchodilators remains the cornerstone of management. Intramuscular corticosteroids may offer a practical alternative to oral steroids in certain emergency settings to reduce relapse risk post-discharge. Continuous score-based nebulized albuterol therapy can be safely and effectively integrated into treatment pathways to improve symptom control. Adjunctive ipratropium bromide inhalation may provide additional bronchodilation in severe cases. However, optimal steroid delivery routes and dosing strategies warrant further validation in pediatric populations.
What the evidence shows
Systemic corticosteroids are essential in reducing airway inflammation and preventing relapse after emergency treatment of acute severe asthma in children. Kirkland et al. (2018) conducted a Cochrane systematic review comparing intramuscular versus oral corticosteroids and found that intramuscular administration may reduce relapse rates following emergency department discharge, particularly when adherence to oral therapy is uncertain. This suggests intramuscular steroids as a viable alternative in emergency settings where oral administration is challenging.
Regarding bronchodilator therapy, Willis et al. (2022) evaluated a score-based continuous albuterol nebulization protocol in pediatric asthma exacerbations, demonstrating safe and effective symptom control with this approach. Continuous nebulized albuterol, titrated by clinical scoring, may optimize bronchodilation while minimizing adverse effects.
Adjunctive inhaled ipratropium bromide has been studied for acute asthma exacerbations in emergency settings. Dotson et al. (2009) reported that ipratropium bromide added to standard beta-agonist therapy can improve lung function and reduce hospital admissions in children with severe exacerbations, supporting its use as an adjunct in emergency care.
The route of corticosteroid administration remains an area of clinical interest. Macias et al. (1997) compared inhaled, intravenous, and oral steroids in moderately severe pediatric asthma exacerbations and found no significant difference in efficacy, although intravenous steroids may be reserved for patients unable to tolerate oral or intramuscular routes.
Rowe et al. (2008) provide a comprehensive evidence-based overview of emergency asthma management, reinforcing the importance of early corticosteroid use, bronchodilator therapy, and supportive care tailored to exacerbation severity.
Caveats and uncertainty
Despite these findings, several limitations persist. The Cochrane review by Kirkland et al. (2018) notes heterogeneity in corticosteroid dosing regimens and patient populations, limiting generalizability. Intramuscular corticosteroids may cause injection site pain and require trained personnel, which could affect feasibility in some emergency settings.
The continuous albuterol therapy protocol studied by Willis et al. (2022) requires clinical scoring systems and monitoring resources that may not be universally available, potentially limiting implementation. Additionally, the long-term safety of continuous nebulized beta-agonists in children needs further study.
Evidence supporting ipratropium bromide adjunctive use primarily derives from smaller trials and observational studies (Dotson et al., 2009), and its benefit may be less pronounced in mild to moderate exacerbations. Optimal timing and dosing strategies remain to be standardized.
Older studies such as Macias et al. (1997) provide foundational data but predate some current inhaler technologies and updated asthma guidelines, necessitating cautious interpretation.
How this may change practice
Emergency clinicians managing pediatric acute severe asthma should prioritize early systemic corticosteroids, considering intramuscular administration when oral intake is compromised or adherence is uncertain. Incorporating continuous, score-guided nebulized albuterol protocols may enhance bronchodilator delivery and symptom control, provided adequate monitoring is feasible.
Adjunctive ipratropium bromide inhalation should be considered in severe exacerbations to reduce hospital admissions and improve lung function. Clinicians should individualize steroid delivery routes based on patient tolerance, severity, and resource availability.
Ongoing education on asthma severity scoring and protocol adherence will be critical to safely implement these strategies. Further research is needed to refine corticosteroid dosing, delivery methods, and adjunctive therapies to optimize outcomes in pediatric emergency asthma care.